Health Canada Approves Johnson & Johnson’s COVID-19 Vaccine
25/11 07:30
Health Canada has authorized the single-shot COVID-19 vaccine of Janssen, a Johnson & Johnson (JNJ) company, to prevent COVID-19 in individuals aged 18 years and older.
Health Canada’s authorization was based on the scientific evidence provided by the company, which included initial data from the Phase 3 ENSEMBLE study. The data demonstrated the efficacy of the vaccine at 85% in preventing the disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.
Notably, the Phase 3 ENSEMBLE study was designed to evaluate the safety and efficacy of the company’s vaccine in protecting against both moderate and severe COVID-19 disease. (See Johnson & Johnson stock charts on TipRanks)
Official Comments
The Global Head, Janssen Research & Development at Johnson & Johnson, Mathai Mammen, said, “As vaccination rates continue to climb, a vaccine that prevents severe disease and protects against COVID-related hospitalization and death ...